Skip to main content

Clinical trial EVICTION

A fist-in-human, two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 as monotherapy and in combination with an Immune Checkpoint Inhibitor, in patients with advanced-stage, relapsed/refractory cancer

Cancers
Organ Multiples
Trial status Trial open for recruitment
Investigator
Trial type
Interventionnal with IMP
Phase Trial phase 1
Academic trial Non
Sponsor Imcheck
EudraCT Identifier 2019-003847-31
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04243499
Inclusion criteria Relasped/refractory patient
Last update